ProCE Banner Activity

Midostaurin Maintenance After Midostaurin Plus Chemotherapy in FLT3-Mutated AML: Post Hoc Analysis in RATIFY

Slideset Download
Conference Coverage
No clear evidence of benefit associated with midostaurin maintenance therapy in this unplanned post hoc subset analysis of the RATIFY trial.

Released: December 13, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology